Royalty Pharma plc (RPRX) stock
RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3051% above fair value
$68.67−0.01 (-0.01%)
Close on Nov 18, 2026Market cap $39.49BP/E 39.0Yield –
Royalty Pharma shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Royalty Pharma's shares outstanding was 557M at Jun 30, 2026. For fiscal 2025 it was 564M, down 5.0% from the year before. The highest annual figure on record is 603M in fiscal 2023.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 564M | -5.0% |
| FY2024 | Dec 31, 2024 | 594M | -1.5% |
| FY2023 | Dec 31, 2023 | 603M | +37.7% |
| FY2022 | Dec 31, 2022 | 438M | +5.6% |
| FY2021 | Dec 31, 2021 | 415M | +10.5% |
| FY2020 | Dec 31, 2020 | 375M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 557M | -1.0% |
| Q1 FY2026 | Mar 31, 2026 | 557M | -3.7% |
| Q4 FY2025 | Dec 31, 2025 | 558M | -5.4% |
| Q3 FY2025 | Sep 30, 2025 | 560M | -5.6% |
| Q2 FY2025 | Jun 30, 2025 | 562M | -5.8% |
| Q1 FY2025 | Mar 31, 2025 | 578M | -3.2% |
| Q4 FY2024 | Dec 31, 2024 | 589M | -1.4% |
| Q3 FY2024 | Sep 30, 2024 | 593M | -1.4% |
| Q2 FY2024 | Jun 30, 2024 | 597M | -1.5% |
| Q1 FY2024 | Mar 31, 2024 | 597M | -1.6% |
| Q4 FY2023 | Dec 31, 2023 | 597M | +35.1% |
| Q3 FY2023 | Sep 30, 2023 | 601M | -1.0% |
| Q2 FY2023 | Jun 30, 2023 | 606M | -0.2% |
| Q1 FY2023 | Mar 31, 2023 | 607M | +0.0% |
| Q4 FY2022 | Dec 31, 2022 | 442M | +2.5% |
| Q3 FY2022 | Sep 30, 2022 | 607M | +0.0% |
| Q2 FY2022 | Jun 30, 2022 | 607M | +0.0% |
| Q1 FY2022 | Mar 31, 2022 | 607M | +0.0% |
| Q4 FY2021 | Dec 31, 2021 | 431M | +8.2% |
| Q3 FY2021 | Sep 30, 2021 | 607M | +64.1% |
| Q2 FY2021 | Jun 30, 2021 | 607M | +71.5% |
| Q1 FY2021 | Mar 31, 2021 | 607M | – |
| Q4 FY2020 | Dec 31, 2020 | 399M | – |
| Q3 FY2020 | Sep 30, 2020 | 370M | – |
| Q2 FY2020 | Jun 30, 2020 | 354M | – |
See a number that looks wrong?